Fig. 7: Interleukin-6 molecular targeting. | Nature Communications

Fig. 7: Interleukin-6 molecular targeting.

From: Inherited ARPC5 mutations cause an actinopathy impairing cell motility and disrupting cytokine signaling

Fig. 7

a Plasma levels of soluble IL-6Rα measured by Luminex assay (top panel) and soluble complexed IL-6/IL-6Rα measured by ELISA (bottom panel) in patient 1 (P1) and five healthy controls (HC). Results are shown as mean + SEM. Data generated from two independent experiments, performed in duplicate each time. b IL-6 trans-signaling modulation in P1’s CD4+ T cells. P1’s cells were pretreated with soluble gp130Fc (1 µg/mL) or tocilizumab (10 µg/mL) for 90 min. A subset of cells was left untreated to serve as control. Then, cells were stimulated with hyper IL-6 (100 ng/mL) for 20 min. A subset of cells was not stimulated to serve as baseline. Sequentially, phosphorylation of STAT3 was measured by flow cytometry (upper panel). The bar graph shows soluble gp130Fc and tocilizumab pretreatment effect on STAT3 phosphorylation in response to hyper IL-6 stimulation compared to untreated (−), stimulated cells (lower panel). This experiment was conducted once. Source data are provided as a Source Data file.

Back to article page